Emmaus Life Sciences, Inc. (OTCMKTS:EMMA – Get Free Report)’s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $0.02 and traded as low as $0.0150. Emmaus Life Sciences shares last traded at $0.0150, with a volume of 26,978 shares changing hands.
Emmaus Life Sciences Stock Down 31.5%
The firm has a market cap of $1.05 million, a PE ratio of -0.17 and a beta of 11.25. The firm’s fifty day simple moving average is $0.05 and its two-hundred day simple moving average is $0.02.
Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported $0.02 EPS for the quarter. The firm had revenue of $6.32 million for the quarter.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and debilitating diseases. The company’s best-known product is Endari, an oral powder formulation of L-glutamine approved in the United States to reduce the frequency of acute complications associated with sickle cell disease in adults and children aged five and older. Emmaus has focused its research and development activities on therapies for diseases with significant unmet medical needs, including hematological and other rare disorders.
Further Reading
- Five stocks we like better than Emmaus Life Sciences
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
